Kodiak Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell KOD and other ETFs, options, and stocks.

About KOD

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. 

CEO
Victor Perlroth
CEOVictor Perlroth
Employees
109
Employees109
Headquarters
Palo Alto, California
HeadquartersPalo Alto, California
Founded
2009
Founded2009
Employees
109
Employees109

KOD Key Statistics

Market cap
486.49M
Market cap486.49M
Price-Earnings ratio
-2.46
Price-Earnings ratio-2.46
Dividend yield
Dividend yield
Average volume
465.81K
Average volume465.81K
High today
$9.63
High today$9.63
Low today
$9.10
Low today$9.10
Open price
$9.33
Open price$9.33
Volume
221.42K
Volume221.42K
52 Week high
$11.60
52 Week high$11.60
52 Week low
$1.92
52 Week low$1.92

KOD News

TipRanks 2d
Kodiak Sciences announces new data from APEX study of KSI-101

Kodiak Sciences (KOD) announced new data from the APEX study of KSI-101 presented at the Retina Society 58th Annual Scientific Meeting in Chicago, Illinois. Dr....

People also own

Based on the portfolios of people who own KOD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.